Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H02 plus CHOP vs Rituximab plus CHOP in untreated DLBCL
CTR20200889Phase 3Completed
- Sponsor
- Shandong New Era Pharmaceutical
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of H02 in diffuse large B-cell lymphoma (DLBCL), sponsored by Shandong New Era Pharmaceutical. Started Aug 2020; status: completed.
02
Drugs
H02
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20200889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200889.